In pharmaceutical manufacturing, the distinction between “re-test date” and “expiry date” is critical. Confusing these two can result in serious GMP violations, product recalls, and regulatory action. This case study explores a real-world scenario where an active pharmaceutical ingredient (API) was mislabeled due to this very confusion, leading to a failed regulatory audit and triggering an internal investigation.
📋 Background of the Incident
The event occurred at a mid-sized pharmaceutical company exporting APIs to the US, EU, and Indian markets. The Quality Assurance (QA) team received an FDA Form 483 observation following a routine inspection, citing “labeling inconsistencies and incorrect use of expiry date on API batch containers.”
Initial Clues:
- 📌 The Certificate of Analysis (CoA) showed a “re-test date” as 18 months post-manufacture
- 📌 The product label printed an “expiry date” of 18 months post-manufacture — matching the re-test period
- 📌 No retesting data was available; the batch was used based on visual inspection alone
This labeling error triggered an investigation and batch quarantine, and it prompted queries from overseas regulatory authorities.
🔍 Root Cause Analysis
The Quality Risk Management (QRM) team initiated a deviation investigation to identify the root cause of the mislabeling. After cross-functional review and audit trail assessment, the following contributors were identified:
- ❗ Labeling SOPs
The failure was not due to an isolated incident but a combination of procedural, training, and system-level gaps.
📖 Regulatory Expectations for Re-Test vs Expiry
Global regulators such as USFDA, EMA, and CDSCO distinguish between expiry dates (for finished drug products) and re-test periods (for APIs or intermediates).
| Term | Definition | Usage |
|---|---|---|
| Re-Test Date | Date after which API must be re-examined to confirm compliance | APIs, intermediates |
| Expiry Date | Final date after which a product is not to be used | Finished drug products |
Misusing these terms can mislead customers and regulatory inspectors — and may cause unsafe drug use if expired materials are mistaken for re-testable ones.
🔧 Corrective and Preventive Actions (CAPA)
To address the non-compliance, the company implemented a comprehensive CAPA plan:
Corrective Actions:
- ✅ Recalled mislabeled API containers from distribution chain
- ✅ Updated labels with accurate “Re-test by” wording per region-specific requirements
- ✅ Trained QA, QC, and warehouse staff on proper date terminology
Preventive Actions:
- ✅ Revised SOPs for labeling APIs and intermediates
- ✅ Implemented dual-date fields in the labeling software (re-test and expiry)
- ✅ Updated label approval checklists to explicitly mention both dates
The CAPA actions were submitted to the FDA and CDSCO with supporting documentation and evidence of effectiveness.
🛠️ Technology and Digital Tools Involved
One overlooked contributor was the legacy labeling software used across production and packaging. It only allowed a single date entry, with no field-specific labeling logic. This was addressed through a digital validation project.
- 💻 New software with dual date validation was deployed
- 💻 Audit trail functionality was enabled for all label edits
- 💻 Role-based approval workflows were implemented for QA and RA
Visit pharma validation resources to understand how such systems can be qualified under GMP standards.
📊 Audit Outcome and Regulatory Closure
After the CAPA was implemented, the FDA conducted a follow-up audit. The following outcomes were reported:
- ✅ No further observations on labeling practices
- ✅ CAPA found effective and sustainable
- ✅ Training records and SOP revisions verified
- ✅ System enhancements accepted by auditors
This closure not only restored the company’s compliance status but also strengthened its internal control framework around re-test and expiry date management.
📑 Lessons Learned and Best Practices
- 💡 Labeling software must accommodate both expiry and re-test fields separately
- 💡 SOPs should provide clear definitions and usage of re-test vs expiry
- 💡 QA review checklists must explicitly include both dates for verification
- 💡 Training should emphasize regulatory language differences
- 💡 Periodic internal audits should include label verification exercises
Reinforce labeling processes through regular audits, data traceability tools, and documented workflows to avoid similar errors.
👥 Stakeholder Involvement in Compliance
In this case, coordination between the QA, regulatory affairs, IT, and training departments played a critical role in addressing the issue.
Key Takeaway:
Compliance is not the responsibility of one department — it requires synchronized action across multiple units to avoid, detect, and correct labeling issues.
Refer to pharma SOP writing examples for cross-functional labeling workflows and audit readiness templates.
📅 Real-World Implications of Mislabeling
This case highlights the potential risks of mislabeling due to confusion between re-test and expiry terminology:
- ❌ Product recalls and reputational damage
- ❌ Regulatory actions, import alerts, and fines
- ❌ Delayed approvals in global markets
- ❌ Loss of customer confidence
Such incidents can be avoided through technology, SOP clarity, training, and audit preparedness.
📚 Conclusion
Confusion between re-test dates and expiry dates is more common than expected, especially in global pharma operations. This case study demonstrates that such errors can be prevented through a structured approach: refining SOPs, using validated labeling tools, implementing cross-checks, and delivering periodic training. Regulatory expectations are clear — companies must distinguish and document both terms accurately to ensure safety, traceability, and compliance.